interventional
N/A
1 country
1
To evaluate the effect of aficamten vs placebo on post-Valsalva left ventricular outflow tract gradients (LVOT-G) in patients with asymptomatic oHCM
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
Not reported
Date not reportedClick on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
July 13, 2026
Actual (reported)Change in post-Valsalva LVOT-G from baseline to Week 54
Change in LAVI, maximal LV wall thickness, LV mass index, LGE percentage by cMRI from baseline to Week 54
Change in SUV by FAPI-PET/CT scan from base-line to Week 54
Change from baseline to Week 54 in echocar-diographic measurements of cardiac structure and of systolic function including: • Left ventricular ejection fraction • Left ventricular end-systolic and end-diastolic volumes (LVESV and LVEDV, re-spectively) • Left atrial volume
Change in biomarkers (NT-proBNP, hsTnT) from baseline to Week 18 and Week 54
Assessed by analysing change in incidence of heart failure, as defined by: • Change in NYHA class to NYHA class 2 or higher at week 18 and Week 54. • Incidence of an official diagnosis of heart failure during the study (at week 54). • Incidence of indicators that correspond with disease progression, such as: atrial fibrillation, indication for septal reduction therapy, ventricular arrhythmias, death.
These entries preserve how the registry describes the intervention. Their treatment roles are shown separately from molecular identities.
Formulated product
MYQORZO 5 mg film-coated tablets
The registry describes a specific formulation. Its exact chemical ingredients and approval status require separate evidence.
FILM-COATED TABLET
View registry recordThe registry names these ingredients. The formulation’s exact chemical form has not been confirmed.
MYQORZO 5 mg film-coated tablets
Named ingredient: aficamten
View registry recordErasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)
Rotterdam, 3015 GD, Netherlands
P.P.M. Zwetsloot
First Submitted
July 13, 2026
Download the complete CTIS (EMA) record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: European Medicines Agency (EMA), Clinical Trials Information System (CTIS). Original record and public documents are available on CTIS.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved:
A Comparison of Two Treatments: Pacemaker and Percutaneous Transluminal Septal Ablation for Hypertrophic Cardiomyopathy
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Contact the study team to confirm eligibility.